CSL Ltd Annual Report 2019

4.4 Key Characteristics of Prior Financial Year Performance Right and Option Grants 9 Feature 2014 2015-2017 Grant Date 1 October 2013 (reported 2014 / expiry 30 September 2020) 1 October 2014 (reported 2015 / expiry 30 September 2019), 1 October 2015 (reported 2016 / expiry 30 September 2020) and 1 October 2016 (reported 2017 / expiry 30 September 2021) Instrument Performance Rights Options and Performance Rights Tranches Two tranches: T1 – 50% of grant and T2 – 50% One tranche of Options and three tranches of Performance Rights Performance Period T1 – three years and T2 – four years Four years Performance Measure 50% of award: rTSR against the MSCI Gross Pharmaceutical Index 50% of award: EPSg Options – individual performance measure Performance Rights T1 – rTSR against selected global Pharmaceutical and Biotechnology companies, and T2 and T3 – EPSg Vesting Schedule rTSR at or below performance of Index – 0% vesting rTSR exceeds performance of Index – 100% vesting EPSg < 8% – 0% vesting EPSg 8% to 12% – Straight line vesting from 50% to 100% vesting EPSg 12% or above – 100% vesting Tranche 1 – rTSR < 50th %ile – 0% vesting 50th %ile – 50% vesting Between 50th and 75th %ile – Straight line vesting from 50% to 100% vesting ≥ 75th %ile – 100% vesting Tranche 2 – EPS target performance < 8% – 0% vesting 8% to 13% – Straight line vesting from 35% to 100% vesting 13% – 100% vesting Tranche 3 – EPS maximum performance 13% – 0% vesting 13% to 15% – Straight line vesting from 0% to 100% vesting 15% – 100% vesting Exercise Price N/A Options only: 2015 – A$73.93, 2016 – A$89.52 and 2017 – A$107.25 Retesting 1 retest per tranche, after an additional 12 months No retest 4.5 Key Characteristics of Prior Financial Year Executive Deferred Incentive Plan Grants Feature 2016 – 2017 Grant Date 1 October 2015 (reported 2016) and 1 October 2016 (reported 2017) Instrument Notional Shares Tranches One Performance Period Three years Performance Measure Individual performance measure Vesting Schedule 100% if performance measure met Exercise Price N/A Settlement Value of the award at vest is based on the five day weighted average share price up to the award maturity date multiplied by the number of Notional Shares held Retesting No retest 9 Details of the grant made 1 October 2017 can be found in section 2.4. CSL Limited Annual Report 2019 69